Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Olivier Rixe"'
Autor:
Diwakar Davar, Roberta Zappasodi, Hong Wang, Girish S. Naik, Takami Sato, Todd Bauer, David Bajor, Olivier Rixe, Walter Newman, Jingjing Qi, Aliya Holland, Phillip Wong, Lianna Sifferlen, Diane Piper, Cynthia A. Sirard, Taha Merghoub, Jedd D. Wolchok, Jason J. Luke
Publikováno v:
Clin Cancer Res
Purpose: TRX518 is a mAb engaging the glucocorticoid-induced TNF receptor−related protein (GITR). This open-label, phase I study (TRX518-003) evaluated the safety and efficacy of repeated dose TRX518 monotherapy and in combination with gemcitabine,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60473b0d4d51a50755b6880e00e30770
https://europepmc.org/articles/PMC9475244/
https://europepmc.org/articles/PMC9475244/
Autor:
Anthony J. Olszanski, Patrick M. Forde, Olivier Rixe, Yanyan Lou, Asha Nayak-Kapoor, David S. Hong, Vi K. Chiu, Floyd Fox, Margaret A. Marshall, Agron Collaku, Tomislav Dragovich, Rom Leidner, James N. Atkins
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 28(3)
Purpose: The aim of the study was to determine safety, antitumor activity, and pharmacodynamic profile of mogamulizumab, an anti-CCR4 monoclonal antibody targeting effector regulatory T cells (Treg) in combination with the checkpoint inhibitor nivolu
Autor:
Montaser Shaheen, Jiayi Yu, Charles J. Link, Yousef Zakharia, Ramses F. Sadek, Robert R. McWilliams, Mohammed M. Milhem, Lucinda Tennant, Joseph J. Drabick, Olivier Rixe, Kenneth F. Grossmann, Gabriela R. Rossi, Nicholas N. Vahanian, Erik L. Brincks, Eugene P. Kennedy, Ravindra Kolhe, David H. Munn, Steven S. Shen, Christopher M Smith, Rafal Pacholczyk
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
BackgroundThe indoleamine 2,3-dioxygenase (IDO) pathway is a key counter-regulatory mechanism that, in cancer, is exploited by tumors to evade antitumor immunity. Indoximod is a small-molecule IDO pathway inhibitor that reverses the immunosuppressive
Autor:
Timothy F. Cloughesy, Andrew B. Lassman, Ray Li, Annick Desjardins, Shilpa Alekar, Carrie T. Taylor, David A. Reardon, Olivier Rixe, Jason H. Williams
Publikováno v:
Investigational new drugs. 38(6)
Background PF-06840003 is a highly selective indoleamine 2, 3-dioxygenase (IDO1) inhibitor with antitumor effects in preclinical models. This first-in-human phase 1 study evaluated safety, pharmacokinetics/pharmacodynamics, and preliminary efficacy i
Autor:
Olivier Rixe, Anthony J. Olszanski, Ken Ogasawara, Maria Palmisano, Jian Yin, Christine Xu, Gopal Krishna, Patricia LoRusso
Publikováno v:
Cancer chemotherapy and pharmacology. 86(1)
Fedratinib, an oral selective kinase inhibitor with activity against both wild type and mutationally activated Janus kinase 2, has been approved for the treatment of adult patients with intermediate-2 or high-risk myelofibrosis by the US Food and Dru
Autor:
Xavier Paliard, Olivier Rixe
Publikováno v:
Targeted Oncology
The clinical development of cancer drugs is rapidly moving from empirical "one drug fits all" or development-by-tumor-type approaches towards more personalized treatment models. A deeper understanding of cancer and the immune system, novel technologi
Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations
Autor:
Olivier Rixe, F. Meiring Nortier, Mehran Makvandi, Sam Simon, Jonathan W. Engle, Jeffrey P. Norenberg, Robert W. Atcher, Michael E. Fassbender, Edouard Dupis, Kevin D. John, Eva R. Birnbaum
Publikováno v:
Targeted Oncology. 13:189-203
Alpha-emitters are radionuclides that decay through the emission of high linear energy transfer α-particles and possess favorable pharmacologic profiles for cancer treatment. When coupled with monoclonal antibodies, peptides, small molecules, or nan
Autor:
Anthony J. Olszanski, Olivier Rixe, Olugbenga Olowokure, Séverine Doroumian, John C. Morris, Jian Y. Yin, Roger B. Cohen, Liji Shen, Igor Puzanov, Patricia LoRusso
Publikováno v:
Anti-Cancer Drugs
Supplemental Digital Content is available in the text.
Taxane–gemcitabine combinations have demonstrated antitumor activity. This phase I study (NCT01001221) aimed to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT
Taxane–gemcitabine combinations have demonstrated antitumor activity. This phase I study (NCT01001221) aimed to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT
Publikováno v:
Expert Opinion on Drug Discovery. 10:925-935
Introduction: Based on extensive preclinical data and abundant evidence for clinical activity, vascular endothelial growth factor receptor (VEGFR) inhibitors are currently standard of care for metastatic renal cell carcinoma (mRCC). Axitinib is one o
Autor:
Laurent Kassalow, Jean François Dedieu, Monica M. Mita, John C. Morris, James L. Wade, John Sarantopoulos, Claudine Wack, Alain C. Mita, A. Craig Lockhart, Olivier Rixe
Publikováno v:
Cancer Chemotherapy and Pharmacology. 74:1113-1124
Cabazitaxel is primarily metabolized by CYP3A. This study evaluated the impact of moderate/strong CYP3A inhibitors [aprepitant (Study Part 2); ketoconazole (Study Part 3)] or strong CYP3A inducers [rifampin (Study Part 4)] on the pharmacokinetics of